14 results
To evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies.The primary efficacy endpoint of this study is * Overall survivalThe secondary efficacy endpoints of this…
To determine the microbiological and clinical cure rate after 14 days.
In this study we aim to evaluate the effectivity of the current, standard treatment of uncomplicated urinary tract infections with fosfomycin, based on urine concentrations of fosfomycin in urine in healthy volunteers after receiving a single, oral…
Primary objectives* To assess the tolerability of regorafenib combined with paclitaxel.Secondary objectives* To assess the effect of regorafenib on uptake of paclitaxel in OGC metastases.* To assess the effect of regorafenib on regorafenib targets…
To determine the influence of esomeprazole on the AUC of regorafenib in patients with mCRC or GIST.
This protocol is designed to determine the safety, tolerability, and efficacy of SGI-110 in combination with irinotecan in previously treated patients with metastatic colorectal cancer who progressed on irinotecan.
The objective of this study is to evaluate efficacy and safety of regorafenib in patients with HCC who have progressed after sorafenib.
- To assess the effectiveness of rectal culture-guided antimicrobial prophylaxis for transrectal prostate biopsy (random ultrasound-guided, targeted MRI-guided or targeted MRI-ultrasound fusion guided) on infectious complications. - To compare the…
Primary objectivesTo determine the bacterial eradication capacity of ertapenem, fosfomycine and gentamicine compared to the reference treatment (ceftriaxone) in uncomplicated anogenital gonococcal infections (at one included infection site) by…
Primary Objective:* The primary objective is to demonstrate the efficacy of avapritinib based on progression-free survival (PFS) determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST),…
Primary:To assess the safety and tolerability of DS-1211b compared with placebo in subjects with PXE.To assess the dose response by assessing the treatment changes in PD endpoints.
The purpose of this study is to determine if the combination of relatlimab and nivolumab improves overall survival (OS) in all randomized participants and participants with PD-L1 CPS >= 1 with later-line metastatic colorectal cancer compared…
To determine the efficacy of oral fosfomycin in comparison to the standard of care oral ciprofloxacin, in the treatment of FUTI after initial empirical treatment with intravenous antibiotics.To describe the pharmokinetic profile of men treated with…
General aim; To dertemine if an alternating regimen of imatinib and regorafenib has sufficient activity and safety to warrant further evaluation as a first line treatment for metastatic GIST.